Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country in November 2023, more than two years after Wegovy, made ...

Gray, or gray market medications, are nothing new, and GLP-1s — the class of weight loss wonder drug that includes ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Zepbound (tirzepatide) is a type of drug called a glucagon-like peptide-1 (GLP-1) receptor agonist. It has the same active ingredient as the type 2 diabetes medication Mounjaro. The Food and Drug ...